BHE pushes the envelope of real-world data analytics with its uniquely powerful solutions. Using cutting-edge data sources and years of research expertise, BHE delivers actionable results that provide insights to support decision making for the life sciences industry, medical groups, and the payer community.
For over 22 years, BHE has provided high-quality, custom research services to provide insights into the value of healthcare services at the population level. Our services include data analytics, models, comparative effectiveness research, and strategic consulting.
BHE continues to advance and innovate in the development and application of technology-enabled, analytic solutions. With years of analytics experience servicing many of the top life science companies, BHE has launched proprietary technology solutions that provide substantial gains in data analysis efficiency, delivering results in hours versus weeks.
BHE has been recognized by Inc. Magazine as one of America’s fastest growing private companies.
Joseph Menzin, Ph.D. is the CEO of BHE, a health analytics research firm that he founded in 1996. He has more than 30 years of experience in the fields of outcomes research, epidemiology, and informatics. Dr. Menzin spearheaded the development and launch of BHE’s flagship analytics platforms. He has authored several dozen papers in medical, pharmacy, and outcomes research journals across a wide range of subjects from clinical trials to program evaluation. He serves as a reviewer for numerous journals, and is a member of many professional associations. Dr. Menzin has a Bachelor’s degree in Economics from the University of Rochester and earned his doctorate in Economics from Boston University.
Jordan Menzin, BA, serves as Chief Technology Officer at Boston Health Economics. His areas of interest include software design and programming, health informatics, and economic modeling. He has been successful in building and maintaining BHE’s software systems and simulation models. Of note, he led the design and implementation of Instant Health Data (IHD) which enables life sciences companies to perform rapid analysis across disparate data sets. He received his Bachelor's in Economics from McGill University.
Matthew Sussman, MA is Head of Modeling & Evidence at BHE. Mr. Sussman has nearly 20 years of business-to-business consulting experience, including more than 11 years of experience in health economics and outcomes research. He has conducted a wide array of outcomes research studies, including cost-effectiveness and budgetary impact analyses, retrospective databases analyses, burden of illness analyses, patient-reported outcomes, clinical trial evaluations, and randomized clinical trials. His experience has spanned a number of disease areas, including immunology, diabetes, cardiovascular disease, chronic respiratory disease, infectious diseases, mental disorders, and oncology. He is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and is an executive committee member of the ISPOR Boston chapter. Mr. Sussman received his undergraduate degree in Business Administration from the University of Michigan’s Ross School of Business and a graduate degree in Economics from Boston University.
Dr. Mark Friedman, MD, serves as Medical Director for Boston Health Economics. He is a part-time practicing internist with more than 20 years of clinical and pharmacoeconomics consulting experience. He has management experience in the formulary and managed care implementation processes and also plays a major role in the design and implementation of clinically-oriented outcomes research studies, including evidence-based medicine studies, clinical-trial–based evaluations, prospective outcomes studies, and economic models. He is a member of the American Board of Internal Medicine and the American College of Physicians. Dr. Friedman is a graduate of Columbia University and attended the Harvard School of Public Health.